MNPR (Monopar Therapeutics) Shares Outstanding (Basic Average): 8.54 Mil (As of Mar. 2026)


MNPR Monopar Therapeutics Inc MNPR
35 GF Score
Price $89.10
! 2 Warning Signs
View Full Analysis

What is Monopar Therapeutics Shares Outstanding (Basic Average)?

Monopar Therapeutics MNPR +9.14% 35 Shares Outstanding (Basic Average) is 8.54 Mil as of Mar. 2026. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Monopar Therapeutics's average basic shares outstanding for the quarter that ended in Mar. 2026 was 8.54 Mil.

Monopar Therapeutics  (NAS:MNPR) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Monopar Therapeutics Shares Outstanding (Basic Average) Related Terms

Monopar Therapeutics Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Monopar Therapeutics's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monopar Therapeutics Shares Outstanding (Basic Average) Chart

Monopar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.49 2.54 2.77 3.79 7.41

Monopar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.99 7.00 7.12 8.53 8.54
MNPR
35GF Score
Monopar Therapeutics Inc MNPR
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 8.54 Mil mean?
Monopar Therapeutics (MNPR) has a Shares Outstanding (Basic Average) of 8.54 Mil as of Mar. 2026. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Monopar Therapeutics and its competitors.
Is Monopar Therapeutics' Shares Outstanding (Basic Average) too high?
Monopar Therapeutics' current Shares Outstanding (Basic Average) is 8.54 Mil. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Shares Outstanding (Basic Average) compare to IPSC and ADCT?
Monopar Therapeutics' Shares Outstanding (Basic Average) of 8.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Monopar Therapeutics and its competitors. Monopar Therapeutics's current Shares Outstanding (Basic Average) is 8.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Shares Outstanding (Basic Average) of 8.54 Mil. The current Shares Outstanding (Basic Average) is 8.54 Mil. Monopar Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Shares Outstanding (Basic Average) is 8.54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score

Get the complete analysis for MNPR

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.10
Price